 |  |
| ABX | ||
| 2,926.289 | ||
| 56.6330 | 0.0197% | |
| BISNIS-27 | ||
| 436.713 | ||
| 0.4480 | 0.0010% | |
| DBX | ||
| 2,892.715 | ||
| -43.1230 | -0.0147% | |
| ECONOMIC30 | ||
| 87.350 | ||
| -0.1400 | -0.0016% | |
| ESGQKEHATI | ||
| 103.200 | ||
| -0.1800 | -0.0017% | |
| ESGSKEHATI | ||
| 104.297 | ||
| -0.1360 | -0.0013% | |
| I-GRADE | ||
| 157.428 | ||
| -0.6240 | -0.0039% | |
| AUDRP | ||
| 12,525.880 | ||
| 14.4600 | 0.1156% | |
| EURRP | ||
| 20,585.090 | ||
| 30.1100 | 0.1465% | |
| JPYRP | ||
| 110.666 | ||
| 0.3194 | 0.2895% | |
| SINRP | ||
| 13,830.430 | ||
| 23.9900 | 0.1738% | |
| USDRP | ||
| 17,732.000 | ||
| 28.0000 | 0.1582% | |
Kandidat obat oral untuk pasien COVID-19 bertambah dengan kehadiran pil antivirus Paxlovid. Berdasarkan hasil sementara uji klinis fase II/III, Paxlovid menunjukkan hasil yang baik sehingga segera diajukan untuk mendapatkan izin penggunaan darurat.
